StockData
bioAffinity Technologies, Inc. logo

bioAffinity Technologies, Inc. (BIAF) stock

BIAFNasdaqServices-Commercial Physical & Biological ResearchFiscal year ends December 31Also trades as BIAFW
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 6, 2026Score 4/3068% below fair value
$2.15+0.22 (+11.40%)

Close on Nov 18, 2026Market cap $17.42MP/E –Yield –

bioAffinity Technologies r&d expenses

Research and development expenses are spending on new products and technology.

bioAffinity Technologies's R&D Expenses for the twelve months ending Jun 30, 2026 was $1.42M, up 5.4% year over year. For fiscal 2025 it was $1.38M, down 5.3% from the year before. The highest annual figure on record is $1.47M in fiscal 2023.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$1.38M-5.3%
FY2024Dec 31, 2024$1.46M-0.5%
FY2023Dec 31, 2023$1.47M+6.5%
FY2022Dec 31, 2022$1.38M+36.8%
FY2021Dec 31, 2021$1.01M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$361.58K+16.1%
Q1 FY2026Mar 31, 2026$349.71K-4.8%
Q4 FY2025Dec 31, 2025$374.01K-4.3%
Q3 FY2025Sep 30, 2025$330.59K+20.4%
Q2 FY2025Jun 30, 2025$311.37K-22.6%
Q1 FY2025Mar 31, 2025$367.39K-6.7%
Q4 FY2024Dec 31, 2024$390.66K-9.7%
Q3 FY2024Sep 30, 2024$274.50K-16.9%
Q2 FY2024Jun 30, 2024$402.43K+20.1%
Q1 FY2024Mar 31, 2024$393.64K+6.5%
Q4 FY2023Dec 31, 2023$432.82K+0.8%
Q3 FY2023Sep 30, 2023$330.38K+3.3%
Q2 FY2023Jun 30, 2023$335.13K+34.9%
Q1 FY2023Mar 31, 2023$369.62K+32.1%
Q4 FY2022Dec 31, 2022$429.24K+230.7%
Q3 FY2022Sep 30, 2022$319.74K-3.3%
Q2 FY2022Jun 30, 2022$248.42K–
Q1 FY2022Mar 31, 2022$279.85K–
Q4 FY2021Dec 31, 2021$129.80K–
Q3 FY2021Sep 30, 2021$330.77K–

More bioAffinity Technologies figures

See a number that looks wrong?